13th Annual Conference of the British HIV Association 29 March–1 April 2007, Brighton, UK

KALETRA™ IN PREGNANCY: A RETROSPECTIVE STUDY OF 100 WOMEN

HIV Med 2007; 8(Suppl. 1):14 (abstract no. P17)

Alison Mears¹, Maytinee Lilaonitkul², David Phillips³, Robyn Cross¹, Fiona Lyons¹, Mette Rodgers³, Graham Taylor² and Annemiek DeRuiter^1
1Department of GUM, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, ²Department of GUM, St Mary’s Hospital, London, UK, ³Department of GUM, Mayday Hospital, London, UK

AIM: To describe the efficacy and tolerability of Kaletra™ and the pregnancy outcome of women conceiving on, or initiating a lopinavir/ritonavir containing regimen in pregnancy.

METHODS: Notes review of 100 pregnant women from three centres who had all received HAART containing Kaletra™. Data were collected regarding maternal CD4 count, viral load, side effects, liver enzymes (LE) and pregnancy outcome.

RESULTS: 82% of women were Black African. Two women were co-infected with hepatitis B (no C). 80 women commenced a Kaletra™ containing regimen at a median gestation of 24 weeks (range 4–39) with a baseline CD4 of 338 cells/µl and viral load of 6712 c/mL. 20% reported nausea or vomiting, 9% diarrhoea with 6% needing an anti-diarrhoeal agent. 22% developed abnormal LE, of which most were transient, leading to one discontinuation. In total 8 patients discontinued Kaletra™ (two due to nausea, one diarrhoea, one abnormal LE, one PET, two nonadherence, one not documented). 83 % achieved an undetectable viral load by the time of delivery. 22% delivered before 37 weeks. Median birth-weight 2950 g (range 440–5530 g), eight women developed PET. Two babies were infected with HIV, both born to women presenting at >39 weeks). 8/20 women who conceived on a Kaletra™ containing regimen developed new side effects but there was no hepatotoxicity and no discontinuations. 12% of these women delivered <37 weeks.

CONCLUSION: In this study Kaletra™ was well tolerated in pregnancy, with very low discontinuation rates due either to side effects or toxicity. However there was an increased preterm birth rate particularly in those initiating HAART during pregnancy.

2007-03-29
P17

Copyright © 2007 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD